234 related articles for article (PubMed ID: 32841261)
21. Clinical and Antibacterial Efficacy and Safety of Besifloxacin Ophthalmic Suspension Compared With Moxifloxacin Ophthalmic Solution.
Garg P; Mathur U; Sony P; Tandon R; Morris TW; Comstock TL
Asia Pac J Ophthalmol (Phila); 2015; 4(3):140-5. PubMed ID: 26065499
[TBL] [Abstract][Full Text] [Related]
22. Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections.
Silverstein BE; Morris TW; Gearinger LS; Decory HH; Comstock TL
Clin Ophthalmol; 2012; 6():1987-96. PubMed ID: 23233796
[TBL] [Abstract][Full Text] [Related]
23. Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile.
Haas W; Gearinger LS; Usner DW; Decory HH; Morris TW
Clin Ophthalmol; 2011; 5():1369-79. PubMed ID: 22034556
[TBL] [Abstract][Full Text] [Related]
24. Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trial.
Abelson MB; Heller W; Shapiro AM; Si E; Hsu P; Bowman LM;
Am J Ophthalmol; 2008 Jun; 145(6):959-65. PubMed ID: 18374301
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.5% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial.
Baiza-Durán L; Olvera-Montaño O; Mercado-Sesma AR; Oregon-Miranda AA; Lizárraga-Corona A; Ochoa-Tabares JC; Pérez-Balbuena AL; Montoya-Sánchez IM; Saucedo-Rodríguez LR; Mora-González A; Gómez-Bastar PA; Villanueva-Najera MA; Sandoval-Delgadillo LI; González-Lomelí M; Páez-Garza JH; Orozco-Carroll M; Casillas-Magallanes M
J Ocul Pharmacol Ther; 2018 Apr; 34(3):250-255. PubMed ID: 29624493
[TBL] [Abstract][Full Text] [Related]
26. Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae.
Haas W; Pillar CM; Hesje CK; Sanfilippo CM; Morris TW
J Antimicrob Chemother; 2010 Jul; 65(7):1441-7. PubMed ID: 20435780
[TBL] [Abstract][Full Text] [Related]
27. Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes.
Morris TW; Gearinger LS; Usner DW; Paterno MR; Decory HH; Comstock TL; Haas W
Clin Ophthalmol; 2011; 5():1359-67. PubMed ID: 22034555
[TBL] [Abstract][Full Text] [Related]
28. Topical ophthalmic moxifloxacin elicits minimal or no selection of fluoroquinolone resistance among bacteria isolated from the skin, nose, and throat.
Lichtenstein SJ; De Leon L; Heller W; Marshall B; Cupp G; Foster K; McLean C; Levy S; Stroman DW
J Pediatr Ophthalmol Strabismus; 2012; 49(2):88-97. PubMed ID: 22074357
[TBL] [Abstract][Full Text] [Related]
29. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans.
Proksch JW; Granvil CP; Siou-Mermet R; Comstock TL; Paterno MR; Ward KW
J Ocul Pharmacol Ther; 2009 Aug; 25(4):335-44. PubMed ID: 19492955
[TBL] [Abstract][Full Text] [Related]
30. Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits.
Proksch JW; Ward KW
J Ocul Pharmacol Ther; 2010 Oct; 26(5):449-58. PubMed ID: 20874668
[TBL] [Abstract][Full Text] [Related]
31. Topical lomefloxacin 0.3% twice daily versus tobramycin 0.3% in acute bacterial conjunctivitis: A multicenter double-blind phase III study.
Gallenga PE; Lobefalo L; Colangelo L; Della Loggia G; Orzalesi N; Velati P; Bujtar E; Ponte F; Damiani S; Bucci MG; Bonini S; Curatola MR; Palma LA; Bonomi L; Tomazzoli Gerosa L; Pagliarusco A; Milan E; Jauch A
Ophthalmologica; 1999; 213(4):250-7. PubMed ID: 10420109
[TBL] [Abstract][Full Text] [Related]
32. Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial keratitis: a retrospective safety surveillance study.
Schechter BA; Parekh JG; Trattler W
J Ocul Pharmacol Ther; 2015 Mar; 31(2):114-21. PubMed ID: 25409447
[TBL] [Abstract][Full Text] [Related]
33. Use of Topical Besifloxacin in the Treatment of Mycobacterium chelonae Ocular Surface Infections.
Nguyen AT; Hong AR; Baqai J; Lubniewski AJ; Huang AJ
Cornea; 2015 Aug; 34(8):967-71. PubMed ID: 26075451
[TBL] [Abstract][Full Text] [Related]
34. Besifloxacin: A Critical Review of Its Characteristics, Properties, and Analytical Methods.
Tótoli EG; Salgado HRN
Crit Rev Anal Chem; 2018 Mar; 48(2):132-142. PubMed ID: 29345957
[TBL] [Abstract][Full Text] [Related]
35. Clinical and bacterial characteristics of acute bacterial conjunctivitis in children in the antibiotic resistance era.
Buznach N; Dagan R; Greenberg D
Pediatr Infect Dis J; 2005 Sep; 24(9):823-8. PubMed ID: 16148850
[TBL] [Abstract][Full Text] [Related]
36. High proportion of nontypeable Streptococcus pneumoniae isolates among sporadic, nonoutbreak cases of bacterial conjunctivitis.
Haas W; Hesje CK; Sanfilippo CM; Morris TW
Curr Eye Res; 2011 Dec; 36(12):1078-85. PubMed ID: 21988450
[TBL] [Abstract][Full Text] [Related]
37. Comparative in vitro susceptibility of besifloxacin and seven comparators against ciprofloxacin- and methicillin-susceptible/nonsusceptible staphylococci.
Miller D; Chang JS; Flynn HW; Alfonso EC
J Ocul Pharmacol Ther; 2013 Apr; 29(3):339-44. PubMed ID: 23289847
[TBL] [Abstract][Full Text] [Related]
38. Non-gonococcal bacterial agents of conjunctivitis and their antibiotic susceptibility patterns in Ilorin, Nigeria.
Olatunji FO; Fadeyi A; Ayanniyi AA; Akanbi AA
Afr J Med Med Sci; 2007 Sep; 36(3):243-7. PubMed ID: 18390064
[TBL] [Abstract][Full Text] [Related]
39. A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis.
Schwab IR; Friedlaender M; McCulley J; Lichtenstein SJ; Moran CT;
Ophthalmology; 2003 Mar; 110(3):457-65. PubMed ID: 12623805
[TBL] [Abstract][Full Text] [Related]
40. Microbiological efficacy of 3-day treatment with azithromycin 1.5% eye-drops for purulent bacterial conjunctivitis.
Denis F; Chaumeil C; Goldschmidt P; Delval L; Pouliquen P; Cochereau I; Chainier D; De Barbeyrac B
Eur J Ophthalmol; 2008; 18(6):858-68. PubMed ID: 18988154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
